Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. hit back against a biotechnology company's bid to avoid selling them a psoriasis drug the startup is developing, complaining that Nimbus Therapeutics LLC's lawsuit seeking to escape its promise to shed the anti-inflammatory is a backdoor way of attacking the pharma giant's completed acquisition of Celgene.